Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases

doi:10.4251/wjgo.v18.i1.113440

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (398)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-6) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-6)

Sum=139

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

127

Sum=177

Publishing Process of This Article

Item

Count

Browse

Download

Sum=81

Jan 15, 2026 (publication date) through Feb 3, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Jan 15, 2026; 18(1): 113440
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.113440

Open in New Tab Full Size Figure Download Figure

Figure 1 Study flowchart. CMT: Chemotherapy; ICI: Immune checkpoint inhibitor; ORR: Objective response rate; DCR: Disease control rate; OS: Overall survival; PFS: Progression-free survival.

Open in New Tab Full Size Figure Download Figure

Figure 2 Kaplan-Meier survival curves of the chemotherapy group and the chemotherapy + immune checkpoint inhibitor group. A: Overall survival; B: Progression-free survival. CMT: Chemotherapy; ICI: Immune checkpoint inhibitor; OS: Overall survival; PFS: Progression-free survival.

Citation: Dai EH, Que SH, Xu H, Zhong GQ, Zhang Z, Liang X, Zhai SW, Li YT, Wang JJ, Feng W. Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases. World J Gastrointest Oncol 2026; 18(1): 113440
URL: https://www.wjgnet.com/1948-5204/full/v18/i1/113440.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i1.113440